Chou Associates Management Inc. Has $843,000 Position in Astrazeneca PLC (AZN)
Chou Associates Management Inc. maintained its stake in Astrazeneca PLC (NYSE:AZN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,000 shares of the company’s stock at the end of the third quarter. Astrazeneca PLC accounts for 0.3% of Chou Associates Management Inc.’s portfolio, making the stock its 22nd largest position. Chou Associates Management Inc.’s holdings in Astrazeneca PLC were worth $843,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of AZN. RDL Financial Inc. bought a new stake in Astrazeneca PLC during the second quarter worth approximately $532,000. Ngam Advisors L.P. boosted its stake in Astrazeneca PLC by 72.4% in the second quarter. Ngam Advisors L.P. now owns 440,868 shares of the company’s stock worth $13,310,000 after buying an additional 185,089 shares during the last quarter. Boyer & Corporon Wealth Management LLC boosted its stake in Astrazeneca PLC by 1.6% in the second quarter. Boyer & Corporon Wealth Management LLC now owns 28,222 shares of the company’s stock worth $852,000 after buying an additional 434 shares during the last quarter. Premier Asset Managment LLC boosted its stake in Astrazeneca PLC by 83.9% in the third quarter. Premier Asset Managment LLC now owns 45,760 shares of the company’s stock worth $1,503,000 after buying an additional 20,875 shares during the last quarter. Finally, Becker Capital Management Inc. bought a new stake in Astrazeneca PLC during the second quarter worth approximately $35,701,000. Institutional investors and hedge funds own 13.05% of the company’s stock.
Astrazeneca PLC (NYSE:AZN) traded up 1.20% during trading on Friday, reaching $28.58. 5,159,759 shares of the company’s stock were exchanged. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.04. The stock’s 50-day moving average is $27.26 and its 200-day moving average is $30.39. The company has a market cap of $72.31 billion, a P/E ratio of 29.33 and a beta of 0.78.
Astrazeneca PLC (NYSE:AZN) last released its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.58. Astrazeneca PLC had a return on equity of 31.30% and a net margin of 10.35%. The business earned $5.70 billion during the quarter, compared to the consensus estimate of $5.95 billion. During the same period last year, the company earned $1.03 earnings per share. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. Analysts predict that Astrazeneca PLC will post $2.07 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Chou Associates Management Inc. Has $843,000 Position in Astrazeneca PLC (AZN)” was posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be accessed at http://www.dailypolitical.com/2017/01/13/chou-associates-management-inc-has-843000-position-in-astrazeneca-plc-azn.html.
AZN has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Tuesday. Piper Jaffray Companies initiated coverage on shares of Astrazeneca PLC in a report on Friday, September 23rd. They set an “overweight” rating for the company. TheStreet cut shares of Astrazeneca PLC to a “hold” rating in a report on Friday, October 14th. Cantor Fitzgerald reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Friday, October 28th. Finally, Shore Capital reiterated a “hold” rating on shares of Astrazeneca PLC in a report on Wednesday, September 28th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $37.27.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.